{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:25:46Z","timestamp":1792977946017,"version":"4.5.0"},"reference-count":237,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grants-in-Aid for Scientific Research","award":["24K10621"],"award-info":[{"award-number":["24K10621"]}]},{"name":"Chugai Foundation for Innovative Drug Discovery Science and BRAIN SCIENCE FOUNDATION","award":["24K10621"],"award-info":[{"award-number":["24K10621"]}],"id":[{"id":"https:\/\/ror.org\/02f5f7v31","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The blood\u2013brain barrier (BBB) acts as a structural and functional barrier for brain homeostasis. This review highlights the pathological contribution of BBB dysfunction to neuroimmunological diseases, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), autoimmune encephalitis (AE), and paraneoplastic neurological syndrome (PNS). The transmigration of massive lymphocytes across the BBB caused by the activation of cell adhesion molecules is involved in the early phase of MS, and dysfunction of the cortical BBB is associated with the atrophy of gray matter in the late phase of MS. At the onset of NMOSD, increased permeability of the BBB causes the entry of circulating AQP4 autoantibodies into the central nervous system (CNS). Recent reports have shown the importance of glucose-regulated protein (GRP) autoantibodies as BBB-reactive autoantibodies in NMOSD, which induce antibody-mediated BBB dysfunction. BBB breakdown has also been observed in MOGAD, NPSLE, and AE with anti-NMDAR antibodies. Our recent report demonstrated the presence of GRP78 autoantibodies in patients with MOGAD and the molecular mechanism responsible for GRP78 autoantibody-mediated BBB impairment. Disruption of the BBB may explain the symptoms in the brain and cerebellum in the development of PNS, as it induces the entry of pathogenic autoantibodies or lymphocytes into the CNS through autoimmunity against tumors in the periphery. GRP78 autoantibodies were detected in paraneoplastic cerebellar degeneration and Lambert\u2013Eaton myasthenic syndrome, and they were associated with cerebellar ataxia with anti-P\/Q type voltage-gated calcium channel antibodies. This review reports that therapies affecting the BBB that are currently available for disease-modifying therapies for neuroimmunological diseases have the potential to prevent BBB damage.<\/jats:p>","DOI":"10.3390\/ijms251910625","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T06:27:31Z","timestamp":1727850451000},"page":"10625","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Blood\u2013Brain Barrier Disruption in Neuroimmunological Disease"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-2939","authenticated-orcid":false,"given":"Fumitaka","family":"Shimizu","sequence":"first","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nakamori","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Schreiner, T.G., Romanescu, C., and Popescu, B.O. (2022). The Blood-Brain Barrier-A Key Player in Multiple Sclerosis Disease Mechanisms. Biomolecules, 12.","DOI":"10.3390\/biom12040538"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/25785826.2018.1531190","article-title":"Blood-brain barrier dysfunction in immuno-mediated neurological diseases","volume":"41","author":"Shimizu","year":"2018","journal-title":"Immunol. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bell, A.H., Miller, S.L., Castillo-Melendez, M., and Malhotra, A. (2020). The neurovascular unit: Effects of brain insults during the perinatal period. Front. Neurosci., 13.","DOI":"10.3389\/fnins.2019.01452"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Brandl, S., and Reindl, M. (2023). Blood-Brain Barrier Breakdown in Neuroinflammation: Current In Vitro Models. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241612699"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.tins.2015.08.003","article-title":"The molecular constituents of the blood-brain barrier","volume":"38","author":"Chow","year":"2015","journal-title":"Trends Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1152\/physrev.00050.2017","article-title":"Blood-Brain Barrier: From Physiology to Disease and Back","volume":"99","author":"Sweeney","year":"2019","journal-title":"Physiol. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuron.2008.01.003","article-title":"The blood-brain barrier in health and chronic neurodegenerative disorders","volume":"57","author":"Zlokovic","year":"2008","journal-title":"Neuron"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1038\/nm.3407","article-title":"Development, maintenance and disruption of the blood-brain barrier","volume":"19","author":"Obermeier","year":"2013","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.it.2015.09.008","article-title":"Antibodies as Mediators of Brain Pathology","volume":"36","author":"Brimberg","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1474-4422(24)00027-9","article-title":"Clinical trials for progressive multiple sclerosis: Progress, new lessons learned, and remaining challenges","volume":"23","author":"Chataway","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.arcmed.2014.11.013","article-title":"Role of the blood-brain barrier in multiple sclerosis","volume":"45","author":"Ortiz","year":"2014","journal-title":"Arch. Med. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: Results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1474-4422(14)70256-X","article-title":"Pathological mechanisms in progressive multiple sclerosis","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1474-4422(14)70264-9","article-title":"Clinical trials in progressive multiple sclerosis: Lessons learned and future perspectives","volume":"14","author":"Ontaneda","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WCO.0000000000000094","article-title":"Relapsing and progressive forms of multiple sclerosis: Insights from pathology","volume":"27","author":"Dutta","year":"2014","journal-title":"Curr. Opin. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic Mechanisms Associated with Different Clinical Courses of Multiple Sclerosis","volume":"9","author":"Lassmann","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/brain\/awq076","article-title":"Evidence for a two-stage disability progression in multiple sclerosis","volume":"133","author":"Leray","year":"2010","journal-title":"Brain"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.bbadis.2010.06.017","article-title":"Disruption of central nervous system barriers in multiple sclerosis","volume":"1812","author":"Alvarez","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1016\/j.febslet.2011.04.066","article-title":"How do immune cells overcome the blood-brain barrier in multiple sclerosis?","volume":"585","author":"Larochelle","year":"2011","journal-title":"FEBS Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/path.1434","article-title":"Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination","volume":"201","author":"Kirk","year":"2003","journal-title":"J. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1750-3639.2002.tb00430.x","article-title":"Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis","volume":"12","author":"Plumb","year":"2002","journal-title":"Brain Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1155\/2006\/709869","article-title":"Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis","volume":"22","author":"Waubant","year":"2006","journal-title":"Dis. Markers"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-2990.2006.00781.x","article-title":"Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis","volume":"33","author":"Leech","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1474-4422(23)00377-0","article-title":"Blood-brain barrier dysfunction in multiple sclerosis: Causes, consequences, and potential effects of therapies","volume":"23","author":"Zierfuss","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Balasa, R., Barcutean, L., Mosora, O., and Manu, D. (2021). Reviewing the Significance of Blood-Brain Barrier Disruption in Multiple Sclerosis Pathology and Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168370"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/brain\/awr268","article-title":"Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on \u03b14 integrin","volume":"134","author":"Ifergan","year":"2011","journal-title":"Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"H1","DOI":"10.1530\/VB-19-0033","article-title":"Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation","volume":"2","author":"Marchetti","year":"2020","journal-title":"Vasc. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.11.008","article-title":"Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease","volume":"147","author":"Mitroulis","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbadis.2010.07.019","article-title":"The blood-brain barrier, chemokines and multiple sclerosis","volume":"1812","author":"Holman","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.nbd.2014.09.016","article-title":"Focal disturbances in the blood-brain barrier are associated with formation of neuroinflammatory lesions","volume":"74","author":"Alvarez","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/01.wnl.0000260064.77700.fd","article-title":"MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS","volume":"68","author":"Miller","year":"2007","journal-title":"Neurology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1093\/brain\/awac389","article-title":"MCAM+ brain endothelial cells contribute to neuroinflammation by recruiting pathogenic CD4+ T lymphocytes","volume":"146","author":"Charabati","year":"2023","journal-title":"Brain"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"eaaw0475","DOI":"10.1126\/scitranslmed.aaw0475","article-title":"Activated leukocyte cell adhesion molecule regulates B lymphocyte migration across central nervous system barriers","volume":"11","author":"Michel","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wimmer, I., Tietz, S., Nishihara, H., Deutsch, U., Sallusto, F., Gosselet, F., Lyck, R., Muller, W.A., Lassmann, H., and Engelhardt, B. (2019). PECAM-1 Stabilizes Blood-Brain Barrier Integrity and Favors Paracellular T-Cell Diapedesis Across the Blood-Brain Barrier During Neuroinflammation. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00711"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"eabj0473","DOI":"10.1126\/scitranslmed.abj0473","article-title":"DICAM promotes TH17 lymphocyte trafficking across the blood-brain barrier during autoimmune neuroinflammation","volume":"14","author":"Charabati","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: Clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/1352458516655217","article-title":"Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis","volume":"23","author":"Nishihara","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: An open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12026-012-8286-6","article-title":"The roles of Galectin-3 in autoimmunity and tumor progression","volume":"52","author":"Radosavljevic","year":"2012","journal-title":"Immunol. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.expneurol.2014.07.020","article-title":"Progressive multiple sclerosis cerebrospinal fluid induces inflammatory demyelination, axonal loss, and astrogliosis in mice","volume":"261","author":"Cristofanilli","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/brain\/awab029","article-title":"Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis","volume":"144","author":"Granziera","year":"2021","journal-title":"Brain"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1177\/1352458519866605","article-title":"Reduced arterial compliance along the cerebrovascular tree predicts cognitive slowing in multiple sclerosis: Evidence for a neurovascular uncoupling hypothesis","volume":"26","author":"Sivakolundu","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/jnnp-2017-316011","article-title":"Vascular pathology in multiple sclerosis: Reframing pathogenesis around the blood-brain barrier","volume":"89","author":"Spencer","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/1352458520912379","article-title":"Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis","volume":"27","author":"Uher","year":"2021","journal-title":"Mult. Scler."},{"key":"ref_48","first-page":"1324","article-title":"Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment na\u00efve relapsing MS patients","volume":"90","author":"Sejbaek","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1177\/1352458519840757","article-title":"Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis","volume":"26","author":"Hyun","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/acn3.51969","article-title":"Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis","volume":"11","author":"Abdelhak","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e221302","DOI":"10.1001\/jamanetworkopen.2022.1302","article-title":"Evaluation of Glial and Neuronal Blood Biomarkers Compared with Clinical Decision Rules in Assessing the Need for Computed Tomography in Patients With Mild Traumatic Brain Injury","volume":"5","author":"Papa","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-019-01980-7","article-title":"The contribution of astrocytes to the neuroinflammatory response in multiple sclerosis and experimental autoimmune encephalomyelitis. Paediatric onset of multiple sclerosis: Analysis of chemokine and cytokine levels in the context of the early clinical course","volume":"137","author":"Brambilla","year":"2019","journal-title":"Acta Neuropathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2016.09.001","article-title":"Soluble serum VCAM-1, whole blood mRNA expression and treatment response in natalizumab-treated multiple sclerosis","volume":"10","author":"Petersen","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.7150\/thno.37142","article-title":"Soluble CD146, a cerebrospinal fluid marker for neuroinflammation, promotes blood-brain barrier dysfunction","volume":"10","author":"Wang","year":"2020","journal-title":"Theranostics"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e1018","DOI":"10.1002\/cti2.1018","article-title":"Genome-wide association studies of multiple sclerosis","volume":"7","author":"Cotsapas","year":"2018","journal-title":"Clin. Transl. Immunol."},{"key":"ref_56","unstructured":"International Multiple Sclerosis Genetics Consortium (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 365, eaav7188."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"B\u00e4cker-Koduah, P., Bellmann-Strobl, J., Scheel, M., Wuerfel, J., Wernecke, K.D., D\u00f6rr, J., Brandt, A.U., and Paul, F. (2020). Vitamin D and Disease Severity in Multiple Sclerosis-Baseline Data from the Randomized Controlled Trial (EVIDIMS). Front. Neurol., 11.","DOI":"10.3389\/fneur.2020.00129"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e1906","DOI":"10.1212\/WNL.0000000000008445","article-title":"Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon \u03b2-1a","volume":"93","author":"Hupperts","year":"2019","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Sangha, A., Quon, M., Pfeffer, G., and Orton, S.M. (2023). The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update. Nutrients, 15.","DOI":"10.3390\/nu15132978"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/cen3.12398","article-title":"Active form of vitamin D directly protects the blood\u2013brain barrier in multiple sclerosis","volume":"8","author":"Takahashi","year":"2017","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","article-title":"Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM","volume":"603","author":"Lanz","year":"2022","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"21","author":"Soldan","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","article-title":"Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk","volume":"116","author":"Tengvall","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jneuroim.2010.08.003","article-title":"Epstein-Barr virus infection of human brain microvessel endothelial cells: A novel role in multiple sclerosis","volume":"230","author":"Casiraghi","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.msard.2017.07.020","article-title":"Smoking and multiple sclerosis: A systematic review and meta-analysis using the Bradford Hill criteria for causation","volume":"17","author":"Degelman","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.brainres.2004.08.043","article-title":"Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution","volume":"1027","author":"Hawkins","year":"2004","journal-title":"Brain Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/jnnp-2023-332643","article-title":"Head trauma results in manyfold increased risk of multiple sclerosis in genetically susceptible individuals","volume":"95","author":"Johansson","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Cash, A., and Theus, M.H. (2020). Mechanisms of Blood-Brain Barrier Dysfunction in Traumatic Brain Injury. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093344"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Habean, M.L., Kaiser, K.E., and Williams, J.L. (2024). Orchestrating Stress Responses in Multiple Sclerosis: A Role for Astrocytic IFN\u03b3 Signaling. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147524"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp.50.5.511","article-title":"A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects","volume":"50","author":"Milligan","year":"1987","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1191\/1352458505ms1190oa","article-title":"The mechanism of action of methylprednisolone in the treatment of multiple sclerosis","volume":"11","author":"Sloka","year":"2005","journal-title":"Mult. Scler."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2249.2002.01725.x","article-title":"Treatment with methylprednisolone in relapses of multiple sclerosis patients: Immunological evidence of immediate and short-term but not long-lasting effects","volume":"127","author":"Barrau","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1017\/S0317167100000883","article-title":"High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium","volume":"27","author":"Gelati","year":"2000","journal-title":"Can. J. Neurol. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1523\/JNEUROSCI.21-01-00092.2001","article-title":"Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury","volume":"21","author":"Xu","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1113\/jphysiol.2005.084038","article-title":"Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system","volume":"565","author":"Silwedel","year":"2005","journal-title":"J. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ana.20161","article-title":"Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro","volume":"56","author":"Kraus","year":"2004","journal-title":"Ann. Neurol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.drudis.2006.06.008","article-title":"The impact of interferon-beta treatment on the blood-brain barrier","volume":"11","author":"Kraus","year":"2006","journal-title":"Drug Discov. Today"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/jnen\/61.8.710","article-title":"Interferon-beta counteracts inflammatory mediator-induced effects on brain endothelial cell tight junction molecules-implications for multiple sclerosis","volume":"61","author":"Kuruganti","year":"2002","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","article-title":"Natalizumab: A review of its use in the management of relapsing-remitting multiple sclerosis","volume":"73","author":"McCormack","year":"2013","journal-title":"Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1177\/1352458518775550","article-title":"Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients","volume":"24","author":"Mills","year":"2018","journal-title":"Mult. Scler."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","article-title":"Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease","volume":"17","author":"Cortese","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bresciani, G., Manai, F., Davinelli, S., Tucci, P., Saso, L., and Amadio, M. (2023). Novel potential pharmacological applications of dimethyl fumarate-an overview and update. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1264842"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/acn3.553","article-title":"The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis","volume":"5","author":"Hammer","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Mills, E.A., Ogrodnik, M.A., Plave, A., and Mao-Draayer, Y. (2018). Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00005"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/acn3.414","article-title":"Effects of fumarates on inflammatory human astrocyte responses and oligodendrocyte differentiation","volume":"4","author":"Galloway","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/WNL.0b013e31820d5ec1","article-title":"Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00401-012-1014-4","article-title":"Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes","volume":"124","author":"Nijl","year":"2012","journal-title":"Acta Neuropathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40263-015-0297-0","article-title":"The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis","volume":"30","author":"Hunter","year":"2016","journal-title":"CNS Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Spampinato, S.F., Obermeier, B., Cotleur, A., Love, A., Takeshita, Y., Sano, Y., Kanda, T., and Ransohoff, R.M. (2015). Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0133392"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.molmed.2015.03.006","article-title":"Sphingosine 1-phosphate signaling at the blood-brain barrier","volume":"21","author":"Prager","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e0121488","DOI":"10.1371\/journal.pone.0121488","article-title":"Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis","volume":"10","author":"Nishihara","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2018.02.016","article-title":"Fingolimod inhibits brain atrophy and promotes brain-derived neurotrophic factor in an animal model of multiple sclerosis","volume":"318","author":"Smith","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ana.21227","article-title":"FTY720 modulates human oligodendrocyte progenitor process extension and survival","volume":"63","author":"Miron","year":"2008","journal-title":"Ann. Neurol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1124\/mol.64.5.1199","article-title":"Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes","volume":"64","author":"Sorensen","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jneuroim.2012.12.005","article-title":"Fingolimod phosphate promotes the neuroprotective effects of microglia","volume":"256","author":"Noda","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1742-2094-8-76","article-title":"Fingolimod modulates microglial activation to augment markers of remyelination","volume":"8","author":"Jackson","year":"2011","journal-title":"J. Neuroinflamm."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1007\/s40265-020-01422-9","article-title":"The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review","volume":"80","author":"Rammohan","year":"2020","journal-title":"Drugs"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","article-title":"Cladribine: Mode of action and implications for treatment of multiple sclerosis","volume":"34","author":"Leist","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1600-0404.2010.01330.x","article-title":"Impact of cladribine on soluble adhesion molecules in multiple sclerosis","volume":"122","author":"Stelmasiak","year":"2010","journal-title":"Acta Neurol. Scand."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e200004","DOI":"10.1212\/NXI.0000000000200004","article-title":"Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients with Multiple Sclerosis","volume":"9","author":"Hansen","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"103465","DOI":"10.1016\/j.autrev.2023.103465","article-title":"A comprehensive review of the advances in neuromyelitis optica spectrum disorder","volume":"22","author":"Siriratnam","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/1352458516663853","article-title":"The impact of 2015 neuromyelitis optica spectrum disorders criteria on diagnostic rates","volume":"23","author":"Hamid","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102522","DOI":"10.1016\/j.msard.2020.102522","article-title":"Risk of relapse in patients with neuromyelitis optica spectrum disorder: Recognition and preventive strategy","volume":"46","author":"Ma","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: From pathophysiology to therapeutic strategies","volume":"18","author":"Correale","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Chihara, N., Aranami, T., Oki, S., Matsuoka, T., Nakamura, M., Kishida, H., Yokoyama, K., Kuroiwa, Y., Hattori, N., and Okamoto, T. (2013). Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0083036"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: State-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/bpa.12099","article-title":"The pathology of an autoimmune astrocytopathy: Lessons learned from neuromyelitis optica","volume":"24","author":"Lucchinetti","year":"2014","journal-title":"Brain Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","article-title":"The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients","volume":"33","author":"Linhares","year":"2013","journal-title":"Clin. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3109\/00207454.2016.1163550","article-title":"Th17 cells in neuromyelitis optica spectrum disorder: A review","volume":"126","author":"Lin","year":"2016","journal-title":"Int. J. Neurosci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/147323001204000427","article-title":"Blood-brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability","volume":"40","author":"Tomizawa","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.msard.2018.10.114","article-title":"Disruption of blood-brain barrier integrity associated with brain lesions in Chinese neuromyelitis optica spectrum disorder patients","volume":"27","author":"You","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1415535","DOI":"10.3389\/fneur.2024.1415535","article-title":"Soluble biomarkers for Neuromyelitis Optica Spectrum Disorders: A mini review","volume":"15","author":"Rodin","year":"2024","journal-title":"Front. Neurol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1177\/1352458510380416","article-title":"Preferential increase of B-cell activating factor in the cerebrospinal fluid of neuromyelitis optica in a white population","volume":"16","author":"Brill","year":"2010","journal-title":"Mult. Scler."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: A cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/acn3.51094","article-title":"The CSF Levels of Neutrophil-Related Chemokines in Patients with Neuromyelitis Optica","volume":"7","author":"Liu","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e61835","DOI":"10.1371\/journal.pone.0061835","article-title":"Characteristic cerebrospinal fluid cytokine\/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis","volume":"8","author":"Matsushita","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1255533","DOI":"10.3389\/fimmu.2023.1255533","article-title":"Interleukin 6: At the interface of human health and disease","volume":"14","author":"Grebenciucova","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1007\/s00415-009-5274-4","article-title":"Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis","volume":"256","author":"Uzawa","year":"2009","journal-title":"J. Neurol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: Significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult. Scler."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.2008.150698","article-title":"Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: An astrocytic damage marker","volume":"80","author":"Misu","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann. Neurol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: Analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/acn3.51167","article-title":"Serum levels of cell adhesion molecules in patients with neuromyelitis optica spectrum disorder","volume":"7","author":"Chang","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1007\/s00415-011-6086-x","article-title":"Cerebrospinal fluid\/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica","volume":"258","author":"Kim","year":"2011","journal-title":"J. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: Frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflamm."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-015-0240-9","article-title":"The cerebrospinal fluid immunoglobulin transcriptome and proteome in neuromyelitis optica reveals central nervous system-specific B cell populations","volume":"12","author":"Kowarik","year":"2015","journal-title":"J. Neuroinflamm."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","article-title":"Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo","volume":"66","author":"Bradl","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-010-0704-z","article-title":"Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination","volume":"120","author":"Sharma","year":"2010","journal-title":"Acta Neuropathol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1212\/NXI.0000000000000727","article-title":"Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD","volume":"7","author":"Jitprapaikulsan","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Schmetzer, O., Lakin, E., Roediger, B., Duchow, A., Asseyer, S., Paul, F., and Siebert, N. (2021). Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder. Front. Neurol., 12.","DOI":"10.3389\/fneur.2021.635419"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"106175","DOI":"10.18632\/oncotarget.22589","article-title":"GRP78 autoantibodies initiate the breakdown of the blood-brain barrier in neuromyelitis optica","volume":"8","author":"Shimizu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: An international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"722237","DOI":"10.3389\/fneur.2021.722237","article-title":"MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis","volume":"12","author":"Clarke","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jnnp-2011-300434","article-title":"Sera from neuromyelitis optica patients disrupt the blood-brain barrier","volume":"83","author":"Shimizu","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/jnnp-2013-305907","article-title":"Autocrine MMP-2\/9 secretion increases the BBB permeability in neuromyelitis optica","volume":"85","author":"Tasaki","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e0122000","DOI":"10.1371\/journal.pone.0122000","article-title":"Markedly increased IP-10 production by blood-brain barrier in neuromyelitis optica","volume":"10","author":"Shimizu","year":"2015","journal-title":"PLoS ONE"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"eaai9111","DOI":"10.1126\/scitranslmed.aai9111","article-title":"Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica","volume":"9","author":"Shimizu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1002\/acn3.50905","article-title":"GRP 78 antibodies are associated with clinical phenotype in neuromyelitis optica","volume":"6","author":"Shimizu","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/1529-0131(200104)44:4<761::AID-ANR132>3.0.CO;2-S","article-title":"The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis","volume":"44","author":"Union","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuroscience.2022.05.038","article-title":"NMO-IgG Induce Interleukin-6 Release via Activation of the NF-\u03baB Signaling Pathway in Astrocytes","volume":"496","author":"Wang","year":"2022","journal-title":"Neuroscience"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"118217","DOI":"10.1016\/j.lfs.2020.118217","article-title":"Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK\/STAT3 signaling pathway","volume":"258","author":"Du","year":"2020","journal-title":"Life Sci."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1212\/NXI.0000000000000311","article-title":"Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro","volume":"4","author":"Takeshita","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol."},{"key":"ref_155","doi-asserted-by":"crossref","unstructured":"Tanaka, K., Kezuka, T., Ishikawa, H., Tanaka, M., Sakimura, K., Abe, M., and Kawamura, M. (2023). Pathogenesis, Clinical Features, and Treatment of Patients with Myelin Oligodendrocyte Glycoprotein (MOG) Autoantibody-Associated Disorders Focusing on Optic Neuritis with Consideration of Autoantibody-Binding Sites: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713368"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Ambrosius, W., Michalak, S., Kozubski, W., and Kalinowska, A. (2020). Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010100"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1212\/WNL.0000000000002844","article-title":"Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD","volume":"87","author":"Wang","year":"2016","journal-title":"Neurology"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.01.007","article-title":"MOG-antibody associated demyelinating disease of the CNS: A clinical and pathological study in Chinese Han patients","volume":"305","author":"Zhou","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1212\/NXI.0000000000000335","article-title":"ADEM-like presentation, anti-MOG antibodies, and MS pathology: Two case reports","volume":"4","author":"Breu","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00401-020-02132-y","article-title":"The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody","volume":"139","author":"Guo","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/brain\/awy151","article-title":"The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells","volume":"141","author":"Saji","year":"2018","journal-title":"Brain"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s12974-020-01824-2","article-title":"Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients","volume":"17","author":"Jarius","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"102005","DOI":"10.1016\/j.msard.2020.102005","article-title":"Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts","volume":"41","author":"Tanaka","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Kothur, K., Wienholt, L., Tantsis, E.M., Earl, J., Bandodkar, S., Prelog, K., Tea, F., Ramanathan, S., Brilot, F., and Dale, R.C. (2016). B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine\/Chemokines Are Elevated in MOG Antibody Associated Demyelination. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149411"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nri2550","article-title":"Autoimmune T cell responses in the central nervous system","volume":"9","author":"Goverman","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1137998","DOI":"10.3389\/fneur.2023.1137998","article-title":"Pathophysiology of myelin oligodendrocyte glycoprotein antibody disease","volume":"14","author":"Corbali","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ana.25291","article-title":"Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein","volume":"84","author":"Spadaro","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e1038","DOI":"10.1212\/NXI.0000000000001038","article-title":"GRP78 Antibodies Are Associated with Blood-Brain Barrier Breakdown in Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder","volume":"9","author":"Shimizu","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Liu, Y., Tu, Z., Zhang, X., Du, K., Xie, Z., and Lin, Z. (2022). Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.998328"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.autrev.2017.04.008","article-title":"The blood brain barrier and neuropsychiatric lupus: New perspectives in light of advances in understanding the neuroimmune interface","volume":"16","author":"Stock","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaut.2016.06.013","article-title":"The diagnosis and clinical management of the neuropsychiatric manifestations of lupus","volume":"74","author":"Govoni","year":"2016","journal-title":"J. Autoimmun."},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Kivity, S., Agmon-Levin, N., Zandman-Goddard, G., Chapman, J., and Shoenfeld, Y. (2015). Neuropsychiatric lupus: A mosaic of clinical presentations. BMC Med., 13.","DOI":"10.1186\/s12916-015-0269-8"},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Lindblom, J., Mohan, C., and Parodis, I. (2022). Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade. Brain Sci., 12.","DOI":"10.3390\/brainsci12020192"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Stock, A.D., Wen, J., and Putterman, C. (2013). Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK\/Fn14 Pathway. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00484"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s10067-007-0722-y","article-title":"Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuropsychiatric systemic lupus erythematosus","volume":"27","author":"Yang","year":"2008","journal-title":"Clin. Rheumatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2014.11.001","article-title":"Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort","volume":"14","author":"Sarbu","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_179","first-page":"e17969","article-title":"Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges","volume":"13","author":"Sarwar","year":"2021","journal-title":"Cureus"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"577518","DOI":"10.1016\/j.jneuroim.2021.577518","article-title":"Neuropathological spectrum in systemic lupus erythematosus: A single institute autopsy experience","volume":"353","author":"Thirunavukkarasu","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S0049-3848(15)50445-3","article-title":"Neuropsychiatric presentations of antiphospholipid antibodies","volume":"135","author":"Gris","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Fleetwood, T., Cantello, R., and Comi, C. (2018). Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.01001"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Mader, S., Brimberg, L., and Diamond, B. (2017). The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01101"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/art.37745","article-title":"IgG anti-NR2 glutamate receptor autoantibodies from patients with systemic lupus erythematosus activate endothelial cells","volume":"65","author":"Yoshio","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1084\/jem.20071285","article-title":"Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis","volume":"204","author":"Matus","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/nm1101-1189","article-title":"A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus","volume":"7","author":"DeGiorgio","year":"2001","journal-title":"Nat. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"19854","DOI":"10.1073\/pnas.0608397104","article-title":"Human lupus autoantibodies against NMDA receptors mediate cognitive impairment","volume":"103","author":"Kowal","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2004.07.011","article-title":"Cognition and immunity; antibody impairs memory","volume":"21","author":"Kowal","year":"2004","journal-title":"Immunity"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/art.38900","article-title":"Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice","volume":"67","author":"Toledo","year":"2015","journal-title":"Arthritis Rheumatol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/ar1198","article-title":"Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: A role for anti-endothelial-cell antibodies","volume":"6","author":"Conti","year":"2004","journal-title":"Arthritis Res. Ther."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/1529-0131(199904)42:4<631::AID-ANR5>3.0.CO;2-X","article-title":"IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner","volume":"42","author":"Carvalho","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00296-022-05104-5","article-title":"The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: The preliminary study","volume":"42","author":"Hrycek","year":"2022","journal-title":"Rheumatol. Int."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1568-9972(02)00063-0","article-title":"Antiendothelial cell antibodies in systemic lupus erythematosus","volume":"1","author":"Renaudineau","year":"2002","journal-title":"Autoimmun. Rev."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"R896","DOI":"10.1186\/ar1759","article-title":"Screening of an endothelial cDNA library identifies the C-terminal region of Nedd5 as a novel autoantigen in systemic lupus erythematosus with psychiatric manifestations","volume":"7","author":"Margutti","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"e000281","DOI":"10.1136\/lupus-2018-000281","article-title":"Elevation of serum anti-glucose-regulated protein 78 antibodies in neuropsychiatric systemic lupus erythematosus","volume":"5","author":"Matsueda","year":"2018","journal-title":"Lupus Sci. Med."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"577620","DOI":"10.1016\/j.jneuroim.2021.577620","article-title":"Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice","volume":"357","author":"Qiao","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_198","doi-asserted-by":"crossref","unstructured":"Tanaka, K., Kawamura, M., Sakimura, K., and Kato, N. (2020). Significance of Autoantibodies in Autoimmune Encephalitis in Relation to Antigen Localization: An Outline of Frequently Reported Autoantibodies with a Non-Systematic Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21144941"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Shan, W., Yang, H., and Wang, Q. (2021). Neuronal Surface Antibody-Medicated Autoimmune Encephalitis (Limbic Encephalitis) in China: A Multiple-Center, Retrospective Study. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.621599"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","article-title":"An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models","volume":"18","author":"Dalmau","year":"2019","journal-title":"Lancet Neurol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: Case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J. Neurosci."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"7292","DOI":"10.1523\/JNEUROSCI.1261-04.2004","article-title":"NMDA receptor GluRepsilon\/NR2 subunits are essential for postsynaptic localization and protein stability of GluRzeta1\/NR1 subunit","volume":"24","author":"Abe","year":"2004","journal-title":"J. Neurosci."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.nbd.2011.09.019","article-title":"Suppression of synaptic plasticity by cerebrospinal fluid from anti-NMDA receptor encephalitis patients","volume":"45","author":"Zhang","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1468-1331.2010.03180.x","article-title":"Brain immunohistopathological study in a patient with anti-NMDAR encephalitis","volume":"18","author":"Streichenberger","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann. Neurol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"102604","DOI":"10.1016\/j.msard.2020.102604","article-title":"The Clinical Features and Prognosis of Anti-NMDAR Encephalitis Depends on Blood Brain Barrier Integrity","volume":"47","author":"Yu","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"153139","DOI":"10.1016\/j.tox.2022.153139","article-title":"N-methyl-D-aspartic acid increases tight junction protein destruction in brain endothelial cell via caveolin-1-associated ERK1\/2 signaling","volume":"470","author":"Mao","year":"2022","journal-title":"Toxicology"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1007\/s10571-023-01371-3","article-title":"Inhibiting PI3K\/Akt-Signaling Pathway Improves Neurobehavior Changes in Anti-NMDAR Encephalitis Mice by Ameliorating Blood-Brain Barrier Disruption and Neuronal Damage","volume":"43","author":"Gong","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Hampe, C.S., and Mitoma, H. (2022). A Breakdown of Immune Tolerance in the Cerebellum. Brain Sci., 12.","DOI":"10.3390\/brainsci12030328"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12311-019-01091-9","article-title":"Consensus Paper. Cerebellar Reserve: From Cerebellar Physiology to Cerebellar Disorders","volume":"19","author":"Mitoma","year":"2020","journal-title":"Cerebellum"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Yshii, L., Bost, C., and Liblau, R. (2020). Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00991"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJM199006283222604","article-title":"Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration","volume":"322","author":"Furneaux","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Hadjivassiliou, M., Manto, M., and Mitoma, H. (2022). Rare Etiologies in Immune-Mediated Cerebellar Ataxias: Diagnostic Challenges. Brain Sci., 12.","DOI":"10.3390\/brainsci12091165"},{"key":"ref_216","first-page":"1602","article-title":"Paraneoplastic Disorders of the Nervous System","volume":"26","author":"Flanagan","year":"2020","journal-title":"Continuum"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1474-4422(08)70060-7","article-title":"Paraneoplastic syndromes of the CNS","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/WNL.42.10.1931","article-title":"Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients","volume":"42","author":"Peterson","year":"1992","journal-title":"Neurology"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00401-017-1802-y","article-title":"Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration","volume":"135","author":"Small","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","article-title":"Lambert-Eaton myasthenic syndrome: From clinical characteristics to therapeutic strategies","volume":"10","author":"Titulaer","year":"2011","journal-title":"Lancet Neurol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.clinph.2014.06.031","article-title":"Lambert-Eaton myasthenic syndrome-diagnosis, pathogenesis and therapy","volume":"125","author":"Hashemolhosseini","year":"2014","journal-title":"Clin. Neurophysiol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ana.10392","article-title":"Reduction of P\/Q-type calcium channels in the postmortem cerebellum of paraneoplastic cerebellar degeneration with Lambert-Eaton myasthenic syndrome","volume":"53","author":"Fukuda","year":"2003","journal-title":"Ann. Neurol."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1093\/brain\/awz168","article-title":"GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome","volume":"142","author":"Shimizu","year":"2019","journal-title":"Brain"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc3701","article-title":"Glucose-regulated proteins in cancer: Molecular mechanisms and therapeutic potential","volume":"14","author":"Lee","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1158\/0008-5472.CAN-06-4686","article-title":"Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78","volume":"67","author":"Jakobsen","year":"2007","journal-title":"Cancer Res."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nbt774","article-title":"Fingerprinting the circulating repertoire of antibodies from cancer patients","volume":"21","author":"Mintz","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12935-023-02931-9","article-title":"Cell surface GRP78: A potential mechanism of therapeutic resistant tumors","volume":"23","author":"Amaresan","year":"2023","journal-title":"Cancer Cell Int."},{"key":"ref_228","first-page":"949","article-title":"Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer","volume":"23","author":"Tsunemi","year":"2010","journal-title":"Oncol. Rep."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"431","DOI":"10.5301\/jbm.5000086","article-title":"The presence of anti-GRP78 antibodies in the serum of patients with colorectal carcinoma: A potential biomarker for early cancer detection","volume":"29","author":"Raiter","year":"2014","journal-title":"Int. J. Biol. Markers"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Gonzalez-Gronow, M., and Pizzo, S.V. (2022). Physiological Roles of the Autoantibodies to the 78-Kilodalton Glucose-Regulated Protein (GRP78) in Cancer and Autoimmune Diseases. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061222"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"103227","DOI":"10.1016\/j.msard.2021.103227","article-title":"Neuromyelitis optica spectrum disorder (NMOSD) associated with cancer: A systematic review","volume":"56","author":"Shahmohammadi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1007\/s10072-023-06952-0","article-title":"The temporal relationship of paraneoplastic aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and breast cancer: A systematic review and meta-analysis","volume":"44","author":"Srichawla","year":"2023","journal-title":"Neurol. Sci."},{"key":"ref_233","doi-asserted-by":"crossref","unstructured":"Duan, Y., Wang, X., Duan, X., Gao, H., Ji, X., Xiao, X., Zhu, F., and Xue, Q. (2022). Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer-A case series. Front. Neurol., 13.","DOI":"10.3389\/fneur.2022.1071519"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.2169\/internalmedicine.9783-22","article-title":"Paraneoplastic Neuromyelitis Optica Spectrum Disorder Related to Glucose-regulated Protein 78 (GRP78) Autoantibodies in a Patient with Lynch Syndrome-associated Colorectal Cancer","volume":"62","author":"Minomo","year":"2023","journal-title":"Intern. Med."},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Amirifar, L., Shamloo, A., Nasiri, R., de Barros, N.R., Wang, Z.Z., Unluturk, B.D., Libanori, A., Ievglevskyi, O., Diltemiz, S.E., and Sances, S. (2022). Brain-on-a-chip: Recent advances in design and techniques for microfluidic models of the brain in health and disease. Biomaterials, 285.","DOI":"10.1016\/j.biomaterials.2022.121531"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12987-018-0108-3","article-title":"A perfused human blood-brain barrier on-a-chip for high-throughput assessment of barrier function and antibody transport","volume":"15","author":"Wevers","year":"2018","journal-title":"Fluids Barriers CNS"},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Ohbuchi, M., Shibuta, M., Tetsuka, K., Sasaki-Iwaoka, H., Oishi, M., Shimizu, F., and Nagasaka, Y. (2024). Modeling of Blood-Brain Barrier (BBB) Dysfunction and Immune Cell Migration Using Human BBB-on-a-Chip for Drug Discovery Research. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25126496"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10625\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:09:16Z","timestamp":1760112556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/19\/10625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":237,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ijms251910625"],"URL":"https:\/\/doi.org\/10.3390\/ijms251910625","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}